These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
533 related articles for article (PubMed ID: 16456814)
1. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Qazilbash MH; Saliba R; De Lima M; Hosing C; Couriel D; Aleman A; Roden L; Champlin R; Giralt SA Cancer; 2006 Mar; 106(5):1084-9. PubMed ID: 16456814 [TBL] [Abstract][Full Text] [Related]
2. Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Gruppo Italiano Trapianti di Midollo Osseo. Majolino I; Vignetti M; Meloni G; Vegna ML; Scimè R; Tringali S; Amaddii G; Coser P; Tribalto M; Raimondi R; Bergonzi C; Sajeva MR; Sica S; Ferrando F; Messina G; Mandelli F Haematologica; 1999 Sep; 84(9):844-52. PubMed ID: 10477460 [TBL] [Abstract][Full Text] [Related]
3. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Mehta J; Tricot G; Jagannath S; Ayers D; Singhal S; Siegel D; Desikan K; Munshi N; Fassas A; Mattox S; Vesole D; Crowley J; Barlogie B Bone Marrow Transplant; 1998 May; 21(9):887-92. PubMed ID: 9613780 [TBL] [Abstract][Full Text] [Related]
4. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279 [TBL] [Abstract][Full Text] [Related]
6. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Kröger N; Perez-Simon JA; Myint H; Klingemann H; Shimoni A; Nagler A; Martino R; Alegre A; Tomas JF; Schwerdtfeger R; Kiehl M; Fauser A; Sayer HG; Leon A; Beyer J; Zabelina T; Ayuk F; San Miguel JF; Brand R; Zander AR Biol Blood Marrow Transplant; 2004 Oct; 10(10):698-708. PubMed ID: 15389436 [TBL] [Abstract][Full Text] [Related]
7. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma. Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951 [TBL] [Abstract][Full Text] [Related]
8. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant. Palumbo A; Falco P; Ambrosini MT; Petrucci MT; Musto P; Caravita T; Pregno P; Bertola A; Cavallo F; Ciccone G; Boccadoro M Eur J Haematol; 2005 Nov; 75(5):391-5. PubMed ID: 16191088 [TBL] [Abstract][Full Text] [Related]
9. Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Alyea E; Weller E; Schlossman R; Canning C; Mauch P; Ng A; Fisher D; Gribben J; Freeman A; Parikh B; Richardson P; Soiffer R; Ritz J; Anderson KC Bone Marrow Transplant; 2003 Dec; 32(12):1145-51. PubMed ID: 14647268 [TBL] [Abstract][Full Text] [Related]
10. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin. Stein RS; Greer JP; Goodman S; Kallianpur A; Ahmed MS; Wolff SN Bone Marrow Transplant; 1999 Feb; 23(3):227-33. PubMed ID: 10084253 [TBL] [Abstract][Full Text] [Related]
12. Autologous and allogeneic stem-cell transplantation as salvage treatment of acute promyelocytic leukemia initially treated with all-trans-retinoic acid: a retrospective analysis of the European acute promyelocytic leukemia group. de Botton S; Fawaz A; Chevret S; Dombret H; Thomas X; Sanz M; Guerci A; San Miguel J; de la Serna J; Stoppa AM; Reman O; Stamatoulas A; Fey M; Cahn JY; Sotto JJ; Bourhis JH; Parry A; Chomienne C; Degos L; Fenaux P J Clin Oncol; 2005 Jan; 23(1):120-6. PubMed ID: 15534358 [TBL] [Abstract][Full Text] [Related]
13. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Blau IW; Basara N; Bischoff M; Günzelmann S; Römer E; Kirsten D; Schmetzer B; Kiehl MG; Fauser AA Bone Marrow Transplant; 2000 Jan; 25(1):41-5. PubMed ID: 10654013 [TBL] [Abstract][Full Text] [Related]
14. Unrelated stem cell transplantation after reduced intensity conditioning for patients with multiple myeloma relapsing after autologous transplantation. Kröger N; Shimoni A; Schilling G; Schwerdtfeger R; Bornhäuser M; Nagler A; Zander AR; Heinzelmann M; Brand R; Gahrton G; Morris C; Niederwieser D; de Witte T Br J Haematol; 2010 Jan; 148(2):323-31. PubMed ID: 19912215 [TBL] [Abstract][Full Text] [Related]
15. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055 [TBL] [Abstract][Full Text] [Related]
16. Non-myeloablative conditioning and allogeneic transplantation for multiple myeloma. Osman K; Elliott B; Mandeli J; Scigliano E; Malone A; Isola L; Grosskreutz C Am J Hematol; 2010 Apr; 85(4):249-54. PubMed ID: 20162541 [TBL] [Abstract][Full Text] [Related]
17. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced. van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513 [TBL] [Abstract][Full Text] [Related]
18. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Terpos E; Apperley JF; Samson D; Giles C; Crawley C; Kanfer E; Olavarria E; Goldman JM; Rahemtulla A Bone Marrow Transplant; 2003 Feb; 31(3):163-70. PubMed ID: 12621476 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of up-front treatment with a double stem cell transplantation in multiple myeloma. Eom KS; Min CK; Lee S; Kim YJ; Kim SY; Kim HJ; Lee JW; Min WS; Kim CC Jpn J Clin Oncol; 2006 Jul; 36(7):432-8. PubMed ID: 16782727 [TBL] [Abstract][Full Text] [Related]
20. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Barlogie B; Kyle RA; Anderson KC; Greipp PR; Lazarus HM; Hurd DD; McCoy J; Moore DF; Dakhil SR; Lanier KS; Chapman RA; Cromer JN; Salmon SE; Durie B; Crowley JC J Clin Oncol; 2006 Feb; 24(6):929-36. PubMed ID: 16432076 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]